Extracellular Vesicles and Biomaterial Design: New Therapies for Cardiac Repair.

Pezzana, Chloé; Agnely, Florence; Bochot, Amélie; Siepmann, Juergen; Menasché, Philippe

Document type :

Article dans une revue scientifique: Article de synthèse/Review paper

DOI :

10.1016/j.molmed.2020.10.006

PMID :

33218944

Permalink :

http://hdl.handle.net/20.500.12210/78857

Title :

Extracellular Vesicles and Biomaterial Design: New Therapies for Cardiac Repair.

Author(s) :

Pezzana, Chloé [Auteur]
Paris-Centre de Recherche Cardiovasculaire [PARCC (UMR_S 970/ U970)]
Agnely, Florence [Auteur]
Institut Galien Paris-Sud [IGPS]
Bochot, Amélie [Auteur]
Institut Galien Paris-Sud [IGPS]
Siepmann, Juergen [Auteur]

Advanced Drug Delivery Systems (ADDS) - U1008
Menasché, Philippe [Auteur]
Paris-Centre de Recherche Cardiovasculaire [PARCC - UMR-S U970]

Journal title :

Trends in Molecular Medicine

Abbreviated title :

Trends Mol Med

Volume number :

Pages :

231-247

Publication date :

2020-11-29

ISSN :

1471-499X

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

The use of extracellular vesicles (EVs) for cardiac regenerative medicine as an alternative to cell transplantation has been demonstrated. For clinical applications, new translational issues have emerged such as ...
Show more >The use of extracellular vesicles (EVs) for cardiac regenerative medicine as an alternative to cell transplantation has been demonstrated. For clinical applications, new translational issues have emerged such as parental cell selection, large-scale production, characterization, and delivery. Two main delivery approaches of EVs for heart repair can be used: either direct myocardial delivery in patients requiring surgery, or intravenous (IV) infusion. To potentiate EV beneficial effects, direct myocardial EV administration can be optimized by controlled-release biomaterials, whereas EV engineering should allow IV-injected EVs to be directed more specifically to the heart. However, new challenges include possible changes in EV bioactivity because of their interactions with the biomaterial, as well as the complexities of EV engineering to improve organ-specific targeting. There is increasing evidence that extracellular vesicles (EVs) mediate the paracrine effects of stem cells. Although EVs have several attractive characteristics, they also raise issues related to delivery. For patients with cardiac disease that require a surgical procedure, direct intramyocardial (IM) administration of EVs is straightforward but its efficacy may be limited by fast wash-out, hence the interest of incorporating EVs into a controlled release polymer to optimize their residence time. For patients without surgical indication, the intravenous (IV) route is attractive because of its lack of invasiveness; however, whole-body distribution limits the fraction of EVs that reach the heart, hence the likely benefits of EV engineering to increase EV homing to the target tissue.Show less >

Language :

Anglais

Audience :

Internationale

Administrative institution(s) :

Université de Lille
Inserm
CHU Lille

Collections :

Advanced Drug Delivery Systems (ADDS) - U1008

Submission date :

2022-12-08T01:35:31Z
2023-03-01T07:20:51Z

Version	Link	Modification date
2	20.500.12210/78857*	2023-03-01T07:12:17Z
1	20.500.12210/78857.1	2022-12-08T01:35:31Z

Extracellular Vesicles and Biomaterial ...

BibTeX

CSV

Excel

RIS

Version history

Extracellular Vesicles and Biomaterial ... BibTeX CSV Excel RIS

Version history

Extracellular Vesicles and Biomaterial ...

BibTeX

CSV

Excel

RIS